AI Medtech company WAYCEN (CEO Kyungnam Kim) has won four CES innovation awards among medical AI companies for the first time ahead of “CES 2023”, the world’s largest electronics trade show, which will be held in Las Vegas, USA, in next January.
According to CES 2023 awards results announced by the Consumer Technology Association (CTA) on February 16, WAYCEN has won four innovation awards for WAYMED Cough, WAYMED Endo PRO and WAYMED EBUS. With two awards each in the areas of digital healthcare and software & mobile apps, it demonstrated the technological leadership of K-medtech.
Winning these awards means that WAYCEN has been recognized worldwide for its technical expertise in real-time image analysis technology and medical big data analysis technology. Winning two awards exclusively for the products using real-time image analysis technology is intended to highlight innovations in WAYCEN’s medical AI solution range. In addition, the three award-winning products were developed through joint research with medical personnel. It speaks volumes in the medical industry that medical professionals and AI-specialized companies have jointly developed clinically useful products through technical verification and thus achieved great achievements.
WAYMED Cough is the world’s first AI-based self-screening app service that enables the assessment of a patient’s respiratory health via an app. This service is the result of joint research by the research team led by Professor Kyeongmin Moon (Department of Pulmonology) at GangNeung Asan Hospital and Dr. Jinhee Jeon (CEO of JIMT). Because it analyzes a user’s respiratory health based on AI and helps people of all genders and ages to easily manage respiratory health, the product has been honored, in two sectors (Digital Health, Software, and Mobile Apps) awards for the CES 2023 Innovation Awards to win.
WAYMED Endo, which was the first in the industry to win the CEO 2022 Innovation Award for the technology that transfers AI technology to an endoscope, has been further developed with the collaboration technology and has won innovation awards for two consecutive years. WAYMED Endo is a software product for endoscopic image analysis, which was researched in a study together with Professor Jie-hyun Kim, Department of Gastroenterology at Gangnam Severance Hospital. While an endoscopy is being performed in an endoscopy room, the AI detects suspicious areas (bumps or dents) in real-time, allowing the medical staff to check the suspicious areas in the endoscopy room immediately.
WAYMED EBUS is a solution that analyzes endobronchial ultrasound endoscopy images in real time and assesses whether malignant lung cancer metastases have occurred. This is also the solution utilizing WAYCEN’s real-time image analysis technology and is the result of joint research with the research team led by Professors Eun Young Kim and Seung Hyeon Yong from the Department of Pulmonology at Severance Hospital. Because it helps sort lymph nodes that need biopsy in EBUS-TBNA tests, which take a lot of time and effort, AI technology saves significant time and money. This led to the recognition of innovative strength.
Due to its unrivaled technology, WAYCEN was selected as “Country Representative Innovation Company 1000” and Top 4 of “Medtech Innovator APAC” Global Health Awards within 3 years of establishment. WAYCEN continues its relentless efforts as an unrivaled global company in the medical AI industry.
